Making Sense of the Expanding Molecular Toolbox for Skin Cancer Diagnosis-Advances in Diagnostic and Prognostic Testing in Cutaneous Melanoma

Video Transcription

Video Summary

Dr. Aaron Farberg, a dermatologist based in Dallas, Texas, discussed advances in diagnostic and prognostic testing for cutaneous melanoma in a detailed presentation. He focused on gene expression profiling (GEP) technologies, specifically the 23-GEP and 31-GEP tests, which aim to improve the accuracy of melanoma diagnosis and prognosis.<br /><br />Dr. Farberg highlighted the challenges in accurately diagnosing melanoma and emphasized the importance of identifying the malignant potential of ambiguous lesions. He explained how GEP technologies analyze gene expression to provide more definitive diagnoses and improve patient outcomes.<br /><br />The presentation included studies demonstrating the effectiveness of GEP testing in stratifying patients and guiding clinical decision-making. Dr. Farberg also discussed the impact of GEP testing on patient management, such as recommending routine imaging for high-risk patients identified by the 31-GEP test.<br /><br />Overall, the presentation underscored the role of GEP technologies in precision medicine for melanoma patients, offering insights into improved outcomes and patient satisfaction with the testing process.

Asset Subtitle

Aaron S. Farberg, MD, FAAD

Meta Tag

Concept Cutaneous Melanoma

Concept Gene Expression Profiling

Concept Melanocytic Lesion

Concept Clinicopathologic Mismatch

Concept Diagnostic Assay

Keywords

Dr. Aaron Farberg

dermatologist

Dallas, Texas

cutaneous melanoma

gene expression profiling

23-GEP test

31-GEP test

Cutaneous Melanoma

Gene Expression Profiling

Melanocytic Lesion

Clinicopathologic Mismatch

Diagnostic Assay